China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Published by: Global Markets Direct

Published: Sep. 30, 2008 - 142 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Definitions

2.2.1 Drug delivery devices

2.2.1.1 Needle-free Injections

2.2.1.2 Inhalation Systems

2.2.1.3 Infusion Systems

3 Healthcare Sector Review

3.1 Healthcare Expenditure

3.2 Healthcare Infrastructure

3.2.1 Healthcare Personnel Data

3.2.2 Healthcare Facilities Data

3.3 Healthcare Policy

4 Drug Delivery Devices in China

4.1 Drug Delivery Devices Overall Revenues (2000-2012)

4.2 Drug Delivery Devices Overall Volume (2000-2012)

4.3 Drug Delivery Devices Company Shares (2005-2006)

5 Inhalation Systems in China

5.1 Inhalation Systems Overall Revenues (2000-2012)

5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)

5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)

5.2 Inhalation Systems Overall Volume (2000-2012)

5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)

5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)

5.3 Inhalation Systems Average Price (2000-2012)

5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)

5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)

5.4 Inhalation Systems Distribution Share (2005-2006)

5.5 Inhalation Systems Company Share (2005-2006)

6 Infusion Systems in China

6.1 Infusion Systems Overall Revenues (2000-2012)

6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)

6.1.2 Syringe Pumps Overall Revenue (2000-2012)

6.1.3 Infusion Pumps Overall Revenues (2000-2012)

6.2 Infusion Systems Overall Volume (2000-2012)

6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)

6.2.2 Syringe Pumps Overall Volume (2000-2012)

6.2.3 Infusion Pumps Overall Volume (2000-2012)

6.3 Infusion Systems Average Price (2000-2012)

6.3.1 Infusion Pumps Average Price (2000-2012)

6.3.2 Syringe Pumps Average Price (2000-2012)

6.3.3 Infusion Disposable Sets Average Price (2000-2012)

6.4 Infusion Systems Distribution Share (2005-2006)

6.5 Infusion Systems Company Share (2005-2006)

7 AstraZeneca PLC Company Profile

7.1 Company Overview

7.2 Business Overview

7.2.1 Products

7.2.2 History

7.3 Locations And Subsidiaries

8 3M Company Profile

8.1 Company Overview

8.2 Business Overview

8.2.1 Consumer and Office

8.2.1.1 Overview

8.2.1.2 Capital Expenditure

8.2.1.3 Market View

8.2.1.4 Key Strategies

8.2.2 Display and Graphics

8.2.2.1 Overview

8.2.2.2 Financials

8.2.2.3 Capital Expenditure

8.2.2.4 Market View

8.2.2.5 Key Strategies

8.2.3 Electro and Communications

8.2.3.1 Overview

8.2.3.2 Financials

8.2.3.3 Capital Expenditure

8.2.3.4 Market View

8.2.3.5 Key Strategies

8.2.4 Health Care

8.2.4.1 Overview

8.2.4.2 Financials

8.2.4.3 Capital Expenditure

8.2.4.4 Market View

8.2.4.5 Key Strategies

8.2.5 Industrial and Transportation

8.2.5.1 Overview

8.2.5.2 Financials

8.2.5.3 Capital Expenditure

8.2.5.4 Market View

8.2.5.5 Key Strategies

8.2.6 Safety, Security and Protection Services

8.2.6.1 Overview

8.2.6.2 Financials

8.2.6.3 Capital Expenditure

8.2.6.4 Market View

8.2.6.5 Key Strategies

8.2.7 Products

8.3 Value Chain Analysis

8.3.1 Manufacturing

8.3.1.1 In House Manufacturing

8.3.2 Product Development

8.3.2.1 Regulatory Approvals

8.3.2.2 Clinical Trials

8.3.2.3 Research and Development

8.3.3 Sales and Marketing

8.3.3.1 Partnerships and Alliances

8.3.3.2 Licensing Agreements

8.3.3.3 E-distribution

8.4 SWOT Analysis

8.4.1 3M Company Strengths

8.4.1.1 Strong performance of Industrial and Transportation segment

8.4.1.2 Focused research and development

8.4.1.3 Decentralized operations

3M Company Weaknesses

8.4.1.4 Increased operating costs in the U.S.

8.4.1.5 Personal care segment’s poor performance

3M Company Opportunities

8.4.1.6 Expanding global presence

8.4.1.7 The liquid crystal display

8.4.1.8 Enhancing brand portfolio

3M Company Threats

8.4.1.9 Foreign currency fluctuations

8.4.1.10 Increasing cost of raw materials

8.4.1.11 Trend for private labels

8.5 Revenue Analysis

8.5.1 Revenue by Segment

8.5.2 Revenue by Geography

8.6 Financial and Operational Review

8.6.1 Financial Statements

8.6.2 Financial Ratios

8.7 Locations And Subsidiaries

9 Baxter International Company Profile

9.1 Company Overview

9.2 Business Overview

9.2.1 BioScience

9.2.1.1 Overview

9.2.1.2 Financials

9.2.1.3 Capital Expenditure

9.2.2 Medication Delivery

9.2.2.1 Overview

9.2.2.2 Financials

9.2.2.3 Capital Expenditure

9.2.3 Renal

9.2.3.1 Overview

9.2.3.2 Financials

9.2.3.3 Capital Expenditure

9.2.4 Products

9.2.5 History

9.3 Value Chain Analysis

9.3.1 Manufacturing

9.3.1.1 In House Manufacturing

9.3.2 Product Development

9.3.2.1 Regulatory Approvals

9.3.2.2 Clinical Trials

9.3.2.3 Research and Development

9.3.3 Sales and Marketing

9.3.3.1 Partnerships and Alliances

9.4 SWOT Analysis

9.4.1 Baxter International Inc. Strengths

9.4.1.1 Diversified geographic presence

9.4.1.2 Sturdy research and development activities

9.4.1.3 Strong financial performance

9.4.2 Baxter International Inc. Weaknesses

9.4.2.1 High levels of inventory

9.4.2.2 Decline in revenues of medication delivery

9.4.2.3 Reduced capital expenditure

9.4.3 Baxter International Inc. Opportunities

9.4.3.1 Co-developing alliances

9.4.3.2 Increasing End Stage Renal Disease patients

9.4.3.3 FDA approval

9.4.4 Baxter International Inc. Threats

9.4.4.1 Legal proceedings

9.4.4.2 Patent litigation

9.4.4.3 Stringent regulations

9.5 Revenue Analysis

9.5.1 Revenue by Segment

9.5.2 Revenue by Geography

9.6 Financial and Operational Review

9.6.1 Financial Statements

9.6.2 Financial Ratios

9.7 Locations And Subsidiaries

9.8 Baxter International Inc. Pipeline Products

9.8.1 Next-Generation Home Hemodialysis Machine

9.8.1.1 Product Overview

9.8.1.2 Product Description

9.8.1.3 Product Status

9.8.1.4 Product Milestone

10 GlaxoSmithKline plc Company Profile

10.1 Company Overview

10.2 Business Overview

10.2.1 Products

10.2.2 History

10.3 Locations And Subsidiaries

11 Novartis AG Company Profile

11.1 Company Overview

11.2 Business Overview

11.2.1 Major Products and Services

11.3 Locations And Subsidiaries

12 Regulation System

12.1 Medical Equipment Approval Process

12.1.1 Classification

12.1.2 Registration and Conformity assessment

12.1.3 China Compulsory Certificate (CCC Mark)

12.1.4 Labeling and Packaging

12.1.5 Registration Fee

12.1.6 Registration Period

12.2 Post Market Surveillance (PMS)

13 Pricing and Reimbursement

14 Distribution Structure

15 Recent Developments

15.1 Strategy And Business Planning

15.1.1 Jul 28, 2008: Mingyuan Enters Strategic Co-Operation Memorandum With GE (CHINA)

15.1.2 Apr 08, 2008: BD Opens New Manufacturing Facility In Suzhou, China

16 Appendix

16.1 Global Markets Direct Research Methodology

16.2 Coverage

16.3 Secondary Research

16.4 Primary Research

16.5 Models

16.6 Forecasts

16.7 Expert Panels

16.8 Currency Conversion

16.9 Contact Us

16.10 Disclaimer

1.1 List of Tables

Table 1: Doctors by Specialty in China, 2003-2007

Table 2: Hospital Wards by Specialty in China, 2003 - 2007

Table 3: Healthcare Institutions in China, 2000-2004

Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2004

Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2004

Table 6: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012

Table 7: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 8: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 9: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012

Table 10: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007

Table 11: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012

Table 12: Drug Delivery Devices, China, Category Volume (Units), 2000-2012

Table 13: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007

Table 14: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012

Table 15: Drug Delivery Devices, China, Company Share by Revenue ($ mn), 2005-2006

Table 16: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 17: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 18: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007

Table 19: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 20: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 21: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 22: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 23: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 24: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007

Table 25: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012

Table 26: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007

Table 27: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012

Table 28: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007

Table 29: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012

Table 30: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007

Table 31: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012

Table 32: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007

Table 33: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012

Table 34: Inhalation Systems, China, Distribution Share by Revenue ($ mn), 2005-2006

Table 35: Inhalation Systems, China, Company Share by Revenue ($ mn), 2005-2006

Table 36: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 37: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 38: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007

Table 39: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 40: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 41: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 42: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 43: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 44: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007

Table 45: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012

Table 46: Infusion Systems, China, Overall Volume (Units), Historic, 2000-2007

Table 47: Infusion Systems, China, Overall Volume (Units), Forecast, 2007-2012

Table 48: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007

Table 49: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012

Table 50: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007

Table 51: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012

Table 52: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007

Table 53: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012

Table 54: Infusion Pumps, China, Average Price ($), Historic, 2000-2007

Table 55: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012

Table 56: Syringe Pumps, China, Average Price ($), Historic, 2000-2007

Table 57: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012

Table 58: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007

Table 59: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012

Table 60: Infusion Systems, China, Distribution Share by Revenue ($ mn), 2005-2006

Table 61: Infusion Systems, China, Company Share by Revenue ($ mn), 2005-2006

Table 62: AstraZeneca PLC, Subsidiaries

Table 63: AstraZeneca PLC, Subsidiaries(Contd..)

Table 64: 3M Company, SWOT Analysis, 2006

Table 65: 3M Company, Revenue by Segment, USD Million, 2003-2007

Table 66: 3M Company, Revenue by Geography, USD Million, 2003-2007

Table 67: 3M Company, Financial Statements, USD Million, 2003-2007

Table 68: 3M Company, Financial Ratios, USD Million, 2003-2007

Table 69: 3M Company, Subsidiaries

Table 70: Baxter International Inc., SWOT Analysis, 2006

Table 71: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007

Table 72: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007

Table 73: Baxter International Inc., Financial Statements, USD Million, 2003-2007

Table 74: Baxter International Inc., Financial Ratios, USD Million, 2003-2007

Table 75: Baxter International Inc., Other Locations

Table 76: Baxter International Inc., Subsidiaries

Table 77: GlaxoSmithKline plc, Subsidiaries

Table 78: GlaxoSmithKline plc, Subsidiaries(Contd..)

Table 79: Novartis Medical Nutrition, Other Locations

Table 80: Novartis Medical Nutrition, Other Locations(Contd..)

Table 81: Currency Conversion from USD to Local Currency at 2007 Constant Rate 1

1.2 List of Figures

Figure 1: Total Healthcare Expenditure in China, 2000 - 2005

Figure 2: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012

Figure 3: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 4: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 5: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012

Figure 6: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007

Figure 7: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012

Figure 8: Drug Delivery Devices, China, Category Volume (Units), 2000-2012

Figure 9: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007

Figure 10: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012

Figure 11: Drug Delivery Devices, China, Company Share (%), 2006

Figure 12: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 13: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 14: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 15: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 16: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 17: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 18: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 19: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 20: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007

Figure 21: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012

Figure 22: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007

Figure 23: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012

Figure 24: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007

Figure 25: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012

Figure 26: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007

Figure 27: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012

Figure 28: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007

Figure 29: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012

Figure 30: Inhalation Systems, China, Distribution Share (%), 2006

Figure 31: Inhalation Systems, China, Company Share (%), 2006

Figure 32: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 33: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 34: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 35: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 36: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 37: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 38: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 39: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 40: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007

Figure 41: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 42: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007

Figure 43: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012

Figure 44: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007

Figure 45: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012

Figure 46: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007

Figure 47: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012

Figure 48: Infusion Pumps, China, Average Price ($), Historic, 2000-2007

Figure 49: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012

Figure 50: Syringe Pumps, China, Average Price ($), Historic, 2000-2007

Figure 51: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012

Figure 52: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007

Figure 53: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012

Figure 54: Infusion Systems, China, Distribution Share (%), 2006

Figure 55: Infusion Systems, China, Company Share (%), 2006

Figure 56: 3M Company, Value Chain Analysis

Figure 57: Baxter International Inc., Value Chain Analysis

Figure 58: Medical Equipment Registration Process in China, 2007

Figure 59: CCC Mark Certification Process in China, 2007

Figure 60: Global Markets Direct Methodology

Abstract

China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the China drug delivery devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices in China

Scope

• The report provides drug delivery devices information broken down into detailed categories and segments in China.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

Reasons to buy

• Gain a strong understanding of the drug delivery devices market in China
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.